IPM was valued at Rs. 178,219 Cr for MAT Oct’21. The retail sector was valued at Rs. 151,183 Cr for this period contributing 85% to IPM. IPM Growth for the month of Oct’21 as compared to the month of Oct’20 was 9.7%. This is the lowest monthly growth in the last 8 months after a low growth of 2.6% reported for Feb’21. Corresponding to low monthly growth, IPM MAT growth also declined slightly after showing a growing trend consistently for the last 7 months from MAT Feb’21. It reported 17.3% for MAT Oct’21 as compared to 17.8% reported for MAT Sept’21. At 15657.3 Cr, the monthly sale reported for Oct’21 is the 5th highest sale value in the last 12 months.

What my Sabziwali taught me about the Internet, Mobile Health & Smartphones

It’s very common for a pharma professional having neighbors, friends and relatives to engage in conversation over medicines. One such conversation – a pleasant surprise – which intrigued me to dig deep into internet dynamics was one with the local roadside Sabziwali.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Marketing

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Policies/Sales

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Strategy

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Thought Leadership
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

IMS Health Market Reflection Report for June 2016

Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of different companies, brands and therapy areas in the Indian Pharmaceutical Market.

Digital in Health – Making Healthcare Patient Centric

Interview with Hanno Wolfram, author of Digital in Health Anup...

Debasish Banerjee’s Journey from Medical Rep to Chief Compliance Officer

For a person wanting to be a doctor, my...

Digital in Pharma and RoI – What and How to Measure Metrics that Matter

To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them. If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.